Welcome to our dedicated page for Know Labs news (Ticker: KNWND), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Know Labs, Inc. (KNWND) is a pioneering force in non-invasive medical diagnostics, developing patented technologies to transform disease detection. This news hub provides investors and healthcare professionals with essential updates on the company's regulatory progress, clinical validations, and strategic partnerships.
Access real-time announcements about breakthrough developments in Know Labs' Bio-RFID technology platform, including FDA submissions and peer-reviewed study results. The curated newsfeed features earnings call summaries, intellectual property milestones, and collaborations advancing portable diagnostic solutions.
Key updates include product development timelines, laboratory testing results, and market expansion strategies. Our aggregation ensures stakeholders never miss material events affecting the company's position in the $50B+ global diagnostics market.
Bookmark this page for streamlined tracking of KNWND's innovation pipeline. Check regularly for verified updates on clinical trials, patent approvals, and financial performance directly from corporate filings and authorized sources.
Know Labs announced that NYSE Regulation has withdrawn its delisting determination and will lift the trading suspension of the company's common stock on the NYSE American. Trading is expected to resume on March 5, 2025, under the symbol 'KNW'.
While the immediate trading suspension is lifted, Know Labs remains under a compliance plan accepted by NYSE American on December 10, 2024. The company has until March 27, 2026, to regain compliance with continued listing standards under Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide. Failure to meet compliance standards or show consistent progress could result in renewed delisting proceedings.
Know Labs (OTC: KNWN) has received approval to begin trading on the OTCQB Venture Market effective February 26, 2025. The company, specializing in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology, will trade under the symbol 'KNWN'. Following a reverse stock split announced by FINRA on February 18, 2025, the symbol temporarily carries a 'D' designation for 20 days from February 19, 2025.
The OTCQB market, recognized by the SEC as an established public market, requires companies to maintain current financial reporting, pass minimum bid price requirements, and undergo annual verification. This upgrade is expected to provide enhanced transparency, improved market depth disclosure, and potentially better liquidity for shareholders.
Know Labs (OTC: KNWND), a leader in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology, has announced updates to its intellectual property portfolio. The company currently holds 325 patents (issued, pending, and in process) and has revealed a library of 1,022 trade secrets codified through the Tangibly platform.
According to an independent analysis by PatSnap, Know Labs' patent portfolio ranks first globally in specific categories of medical diagnostics and industrial process control. The company's IP strategy involves both patents and trade secrets, with the latter being disclosed publicly for the first time as part of their Know Labs Technology Licensing (KTL) initiative.
The slight reduction from previously reported 332 patent assets is attributed to combining provisional patents into utility patents and strategic abandonment of less critical pending patents. The company emphasizes that both patents and trade secrets will continue to grow as innovation progresses.
FAQ
What is the current stock price of Know Labs (KNWND)?
What is the market cap of Know Labs (KNWND)?
